NTP listed ethyl acrylate as “reasonably anticipated to cause cancer in humans” in its Fifth Annual Report on Carcinogens (ROC) in 1989. The listing was based on forestomach tumors observed in oral gavage studies in rats and mice reported by NTP in 1986. Tumor increases had not been reported in cancer studies conducted by inhalation, dermal, or in drinking water. In 1997, BAMM petitioned NTP to reconsider its listing decision based on studies performed by NTP scientists and others that cast doubt on the relevance of the oral gavage studies to humans. In response, the NTP initiated a formal reevaluation that included three scientific committee reviews, the last from the NTP Board of Scientific Counselors, and a report that was reviewed by both the Director of NTP and the Secretary of Health and Human Services before being transmitted to Congress. Key to the NTP evaluation were mechanistic data demonstrating that ethyl acrylate causes tumors only in rodent forestomachs, and only after gavage dosing at extremely high levels for long periods has overwhelmed the forestomach tissue’s detoxification mechanisms. NTP also considered evidence supporting the conclusion that EA should be considered non-genotoxic. (NTP, 1998, p. 14)

Following its review, the NTP determined that the forestomach tumors reported in its 1986 gavage studies were not relevant to humans and delisted ethyl acrylate as a carcinogen in its Ninth Report on Carcinogens (ROC) in 2000. The NTP Executive Committee’s Interagency Working Group for the Ninth ROC included representatives of eleven federal agencies. In the Ninth ROC, NTP explained that the delisting was:

based on the fact that the forestomach tumors induced in animal studies were seen only when the chemical was administered by gavage at high concentrations of ethyl acrylate that induced marked local irritation and cellular proliferation, and because significant chronic human exposure to high concentrations of ethyl acrylate monomer is unlikely. (See Ninth ROC, App. B, p. B-2).

Thus, NTP formally reversed itself and found the forestomach tumors following gavage dosing not relevant to human carcinogenicity. The NTP delisting decision was based on data that was not available when NTP made its original listing (and also was not available when IARC made its listing decision in the late 1980’s).

References:


Disclaimer
This document is not intended to be comprehensive. It is provided solely as background information and should not substitute for an up-to-date Safety Data Sheet or research should specific regulatory or other legal questions arise. It is not intended to be a statement of legal requirements when using or handling acrylates. Although the information is believed to be accurate as of the last update, new information may become available and regulations frequently change, and no warranty, expressed or implied, is made concerning the contents. In addition, many states and localities adopt their own regulations, which are not covered by this summary or on the BAMM website. In all events, the user should consult applicable laws and regulations, as well as their supplier’s Safety Data Sheet, for current information and requirements. NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY, OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED, IS MADE CONCERNING THE INFORMATION PROVIDED HEREIN.